NCT00861419 2017-02-08
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
Amgen
Phase 1 Completed
Clinical Trials
8 trialsNCT00094835 2016-03-24
Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Amgen
Phase 1/2 Completed
NCT00121628 2013-10-09
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
Amgen
Phase 2 Completed
NCT00322400 2013-07-31
Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer
Amgen
Phase 1 Completed
NCT00089960 2013-04-29
Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)
Amgen
Phase 2 Completed
NCT00101894 2012-09-17
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
Amgen
Phase 1 Completed
NCT01386866 2011-07-15
Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT01235416 2011-01-21
A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors
Amgen
Phase 1 Completed